Tag: Northwest Biotherapeutics

  • Biotech Losers: Cell Therapeutics Inc. (NASDAQ:CTIC), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (NASDAQ:NWBO), Synageva BioPharma Corp (NASDAQ:GEVA)

    Cell Therapeutics Inc. (NASDAQ:CTIC) on Feb. 27 reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the UK, has published final guidance recommending prescription of PIXUVRI® (pixantrone) as a cost-effective monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), which includes diffuse large B-cell lymphoma. Cell Therapeutics Inc. (NASDAQ:CTIC) stock opened at $3.70 in last session, and closed at $3.63, while the day range of Cell Therapeutics Inc. (NASDAQ:CTIC) stock is $3.51 – $3.74. The stock showed a positive weekly performance of 1.97%.

    Celldex Therapeutics Inc. (NASDAQ:CLDX) Monday reported a net loss of $22.06 million or $0.27 per share for the fourth quarter of 2013 compared to net loss of $16.81 million, or $0.27 per share for the same quarter last year. Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock opened at $27.36 in last session, and closed at $26.28 by losing -10.06%. The 52 week range of $9.13 – $38.84. Company’s market capitalization is $2.13B.

    Ten years ago, cash-strapped biotechnology company Northwest Biotherapeutics Inc. (NASDAQ:NWBO) was down to three employees and one week from closing its doors when a financial backer came forward at the annual JP Morgan Healthcare Conference. Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) stock decreased -10.30% and finished the last session at $6.36. The EPS of the stock remained -3.46. Company’s market capitalization is $224.35M.

    Synageva BioPharma Corp. (GEVA: Quote) Monday posted fourth-quarter net loss of $30.7 million, or $1.00 per share, wider than $15.2 million, or $0.62 per share in the comparable quarter last year. Synageva BioPharma Corp (NASDAQ:GEVA) stock opened the session at $113.54, and closed the session at $101.36. The 52 week range of the Synageva BioPharma Corp (NASDAQ:GEVA) stock remained $38.58 – 119.42 and the day range was $101.03 – 114.43.